Fox Business - The Power to Prosper
Search Site

Watson Pharmaceuticals

U.S. Seeks $1B from Drug Firms Delaying Generics

The U.S. Federal Trade Commission seeks a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired, an FTC official told a legal conference on Friday.The antitrust agency alleges that the way drugmakers settle patent-related lawsuits hurts consumers by making drugs more expensive. In the settlements, makers of brand-name drugs pay millions of dollars to generics companies while they delay putting their products on the U.S. market.In June, the U.S. Supreme Court ruled that the FTC may challenge the deals in federal courts.A panel moderator at the American Bar Association's spring antitrust meeting asked Deborah Feinstein, the director of the FTC's Bureau of Competition, what developments to expect in the coming year."My hope is that we get a billion-dollar settlement in one of the patent-settlement, pay-for-delay cases," Feinstein responded, giving no indication that any settl...

Read More

  1. AstraZeneca Settles Suit, Protecting Crestor

    AstraZeneca PLC (AZN) Monday said it had settled a long-running patent lawsuit with three generic drug makers, in a move which will help safeguard revenue from top-s...

  2. Top Court to Decide on Deals to Delay Cheaper Drugs

    The U.S. Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper...

  3. Actavis CEO on Reducing Health-Care Costs with Biosimilar Drugs

    Actavis CEO Paul Bisaro on the latest trends in pharmaceuticals and the impact of the health-care law.

  4. Concerns Rise Ahead of Amgen's Business Update Thursday

    Amgen Inc. (AMGN) is the world's largest biotechnology company, but it is beginning to face Big Pharma-type problems that include looming patent expirations for seve...

  5. Pfizer Wins Rapamune Patent Suit Against Actavis

    Pfizer Inc. (PFE) said it won its patent infringement suit against Actavis Inc. (ACT) in a federal court in Delaware, which now prevents Actavis from marketing its g...

  6. Actavis forecasts 2012 sales in excess of 2 billion euros

    Actavis, the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than 2 billion euros ($2.6 billion) this year, drive...

  7. FTC Clears Watson-Actavis Deal, With Conditions

    The Federal Trade Commission on Monday cleared Watson Pharmaceuticals Inc.'s (WPI) proposed $5.9 billion acquisition of Swiss rival Actavis, but required the compani...

  8. U.S. High Court Rejects Allergan Patent Appeal

    The U.S. Supreme Court on Monday rejected Allergan Inc's appeal of a ruling that favored generic drugmaker Watson Pharmaceuticals Inc over patents related to the tre...

  9. FDA Withdrawing Approval of 1 Impax/Teva Generic Wellbutrin Product

    One version of generic Wellbutrin comes off U.S. market-FDA tests show generic not as effective as brand name-FDA asking other drug makers to conduct additional test...

  10. U.S. finds no wrongdoing in Yasmin patent settlement

    U.S. antitrust regulators found no wrongdoing in a deal made four years ago between German drugmaker Bayer AG and a division of Teva Pharmaceuticals to end patent li...

  11. Jumbo Deals Push Monthly Corporate Bond Volume to $115 Billion

    Two jumbo-size bond deals are bringing some life back to the corporate-debt market after a couple of quiet sessions.Watson Pharmaceuticals Inc. (WPI) has a prescript...

  12. Health Care Sector Wrap

    The Health Care sector (XLV) showed little change during trading today while the S&P 500 rose 0.6%.The ETF, as a proxy for the sector, tracked closer to the overall ...

  1. SCOTUS: FTC can Challenge Drug Deals

    The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals brand-name drug companies make with generic rivals that keep cheaper pro...

  2. Actavis to Buy Warner Chilcott for $5 Billion in Stock

    Drug maker Actavis Inc. (ACT) agreed to acquire Warner Chilcott PLC (WCRX) for about $5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specia...

  3. Actavis to Buy Warner Chilcott For $5 Billion in Stock

    Drug maker Actavis Inc. (ACT) agreed to acquire Warner Chilcott PLC (WCRX) for about $5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specia...

  4. Drugmaker Actavis in Talks to Buy Warner Chilcott

    Generic drugmaker Actavis Inc, formerly Watson Pharmaceuticals, said on Friday that it was in early stage discussions to buy specialty pharmaceutical company Warner ...

  5. Actavis Swings to 1st-Quarter Loss on Charges; Raises Year View

    Actavis Inc. (ACT) swung to a first-quarter loss as acquisition, licensing and other charges masked the drug maker's revenue growth, while adjusted earnings topped c...

  6. Actavis Temporarily Enjoined From Selling Generic of AstraZeneca's Pulmicort Respules

    Actavis Inc. (ACT) confirmed a New Jersey court has granted a motion from AstraZeneca PLC (AZN) seeking a temporary restraining order to prevent Actavis from further...

  7. Supreme Court Concerned About Drug Patent Settlements

    Several members of the Supreme Court expressed concern Monday about patent settlements in which brand-name pharmaceutical companies pay generic-drug makers to drop p...

‹ Prev123Next ›
Freebase CC-BY
Source: Watson Pharmaceuticals on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL